Avista commits USD48.5m to develop nasal drug delivery technology
Private equity firm Avista Capital Partners has committed to invest USD48.5m in OptiNose, which has developed a nasal drug delivery technology that enables administration of drugs deep in the nasal cavity, enabling the treatment of both local and systemic disease. In conjunction with this investment, OptiNose will reincorporate in the




